hirudoid 5g/14g crm
cfl ph. - mucopolysaccharide poly sulfate(heparinoid) - crm - 250iu/g - 5g/14g
fragmin 25000 iuml
pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 5000 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism.unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
fragmin 2500 i.u 0.2 ml
pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 2500 iu / 0.2 ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections.cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
fragmin 2500 i.uml
pfizer pfe pharmaceuticals israel ltd - dalteparin sodium - solution for injection - dalteparin sodium 2500 iu/ml - dalteparin - dalteparin - prevention of clotting during haemodialysis and haemofiltration in connection with acute renal failure or chronic renal insufficiency. treatment of acute deep venous thrombosis and/or pulmonary embolism. unstable coronary artery disease. thromboprophylaxis in conjunction with surgery. prophylaxis in patients with substantially increased risk for venous thromboembolism and that are temporarily immobilized due to acute illness such as cardiac insufficiency respiratory insufficiency and severe infections. cancer patients : treatment and secondary prevention of deep-vein thrombosis and/or pulmonary embolism.
fragmin injection 25000 iuml
pfizer private limited - dalteparin sodium - injection - 25000 iu/ml - dalteparin sodium 25000 iu/ml
naropin infusion 0.2%
dch auriga singapore - ropivacaine hcl - injection - 2 mg/ml - ropivacaine hcl 2 mg/ml
naropin injection 1%
dch auriga singapore - ropivacaine hcl - injection - 10 mg/ml - ropivacaine hcl 10 mg/ml
fragmin injection 10000 iuml (with preservative)
pfizer private limited - dalteparin sodium - injection - 10000 iu/ml - dalteparin sodium 10000 iu/ml
marcain injection 0.5% (polyamp duofit)
dch auriga singapore - bupivacaine hcl - injection - 5 mg/ml - bupivacaine hcl 5 mg/ml
xylocaine injection 1% (5ml)
dch auriga singapore - lignocaine hcl anhydrous - injection - 50 mg/5 ml - lignocaine hcl anhydrous 50 mg/5 ml